Structured intelligence on corporate strategy, market moves, and industry signals.
Each entry is a briefing, not a headline: event summary, strategic context, and what to watch next.
A Company Pulse is our reading of what a company says in its own press release, with the questions we would want answered. It is not verified reporting and it is not an endorsement. Pulses are made from press releases we collect from several sources, including Wire. Nobody can pay for a Pulse.
Outlook Therapeutics' resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for wet AMD has been rejected with a Complete Response Letter (CRL) by the FDA.
Bridge tolls across seven Bay Area state-owned bridges will increase by 50 cents starting January 1, 2026, with phased increases continuing through 2030.
MAX Power Mining Corp. has secured investment from renowned gold and silver investor Eric Sprott and a strategic partnership with Vietnam-based Bitexco’s Big Energy affiliate.
Organigram is increasing its investment in Phylos Bioscience, consolidating existing debt with a US$3 million advance, bringing the total loan principal to US$10 million.
Ultragenyx has completed the rolling submission of a Biologics License Application (BLA) to the U.S. FDA for DTX401 (pariglasgene brecaparvovec), a gene therapy for Glycogen Storage Disease Type Ia (GSDIa).
